10月9日,上海创新药企复宏汉霖宣布,其自研的创新型PD-1抑制剂H药“汉斯状”联合化疗新辅助/单药辅助治疗胃癌的III期临床研究(ASTRUM-006)达到主要终点。这是全球首个胃癌围术期(术前/术后)以免疫单药取代术后辅助化疗的治疗方案,实现了该领域的重大突破。ASTRUM-006是一项针对早期胃癌患者的随机、双盲、多中心的III期临床研究,旨在评估汉斯状®联合化疗对比安慰剂联合化疗新辅助/...
Source Link10月9日,上海创新药企复宏汉霖宣布,其自研的创新型PD-1抑制剂H药“汉斯状”联合化疗新辅助/单药辅助治疗胃癌的III期临床研究(ASTRUM-006)达到主要终点。这是全球首个胃癌围术期(术前/术后)以免疫单药取代术后辅助化疗的治疗方案,实现了该领域的重大突破。ASTRUM-006是一项针对早期胃癌患者的随机、双盲、多中心的III期临床研究,旨在评估汉斯状®联合化疗对比安慰剂联合化疗新辅助/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.